# Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier

Source: https://onco.cc/key-papers/paper-kerr-92-gene-cancer-classifier-clin-cancer-res-2012/  
OnCo record `paper-kerr-92-gene-cancer-classifier-clin-cancer-res-2012` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A blinded multisite study of 790 tumours showing how often a 92-gene test named a cancer's tissue of origin correctly.

## Summary

Overall sensitivity was 87 per cent for tumour type and 82 per cent for subtype.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Clinical Cancer Research
- Year: 2012
- DOI: 10.1158/1078-0432.CCR-12-0920
- Authors: Kerr SE, Schnabel CA, Sullivan PS, et al.
- Findings: Sensitivity 87% for tumour type and 82% for subtype.
- What it means: Gene activity often points to where a cancer of unknown primary started.
- Caveats: Tumours of known origin were used as the reference.

## Sources

- Kerr et al., Clin Cancer Res 2012: https://doi.org/10.1158/1078-0432.CCR-12-0920
- PubMed: https://pubmed.ncbi.nlm.nih.gov/22648269/

## Connected records

- cancers: [Cancer of unknown primary (CUP)](https://onco.cc/cancers/cancer-of-unknown-primary/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [CancerTYPE ID](https://onco.cc/drugs/cancertype-id/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-kerr-92-gene-cancer-classifier-clin-cancer-res-2012.json